NCT06816433 - Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions

Post Traumatic Stress Disorder

Interventions

DRUG

Intervention D SLS-002

SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.

DRUG

Intervention D Placebo

A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.

Trial Locations (10)

14221

Upstate Clinical Research Associates, LLC, Williamsville

30318

Advanced Discovery Research, Atlanta

33032

Homestead Associates in Research, Inc., Miami

41075

Cincinnati Veteran's Affairs Medical Center, Fort Thomas

78236

Wilford Hall Ambulatory Surgical Center (WHASC), San Antonio

96859

Tripler Army Medical Center (TAMC), Tripler AMC

98433

Madigan Army Medical Center, Joint Base Lewis McChord

85012-1839

Phoenix VA Healthcare System, Phoenix

20889-5632

Walter Reed National Military Medical Center (WRNMC), Bethesda

22060-5285

Alexander T. Augusta Military Medical Center (ATAMMC):, Fort Belvoir